* xCures and CureScience form partnership to provide patient centric solutions
* COVID-19 patient treated with Mesenchymal Stem Cells (MSCs) - First in the US
* Dr. Boris Reznik joins CureScience's Advisory Board Member
* CureScience Institute expands Vision and Mission
* Gary Shields joins the Institute's Advisory Board
* Dr. Marincola joins the Institute's Advisory Board
* Curtana Pharmaceuticals’ CT-179 Receives Rare Pediatric Disease Designation
* Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome
* CureScience CEO wants to ‘cocreate, not compete’ to advance health care
A personalized vaccine program enabled by CureScience for cancer patients. The vaccine is tailored to the individual's tumor mutations. The neoepitope is predicted based on individual's sequenced data. Based on the predictions, an optimized peptide combination is translated into therapy.
Read More
© 2022 CureScience | Developed by FiCity.Org | Terms of Use | Privacy Policy
CureScience™ Institute is a registered nonprofit under code 501(c)(3). Your donation is tax deductible.
